Ongoing clinical studies of LGH447 as a single agent and in combination with PI3K inhibitor BYL719 in advanced MM are anticipated to expedite the progression of Pim inhibitors with rational partners to the clinic and are eagerly awaited. This evidence concerns the gene PIM1 and Miyoshi myopathy.